Company intelligence / Profile preview
Rakuten Medical, Inc.
- Ownership
- Private
- Employees
- ~220
- Development stage
- Commercial
Overview
Rakuten Medical’s lead program ASP-1929 has shown preliminary safety and efficacy data when used alone or combined with anti-PD1 therapy. In Japan, the therapy received regulatory approval for certain head and neck cancers. A global Phase 3 trial for first-line recurrent head and neck cancer was initiated in January 2025. The company continues to expand its pipeline using the Alluminox™ platform[1][2][4].
- Therapeutic areas
- Oncology
- Modalities
- Photoimmunotherapy (antibody-dye conjugates)biologics
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Rakuten Medical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rakuten Medical, Inc..